The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

被引：0
|
作者：
Wilson, J. M. [1 ]
Nikooienejad, A. [1 ]
Bowsman, L. M. [1 ]
Schroeder, J. M. [1 ]
Hamlin, D. M. [1 ]
Robins, D. A. [1 ]
Riesmeyer, J. S. [1 ]
Haupt, A. [1 ]
Duffin, K. L. [1 ]
Ruotolo, G. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1161
引用
收藏
页码：S558 / S559
页数：2
相关论文
共 50 条
  • [41] The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist
    Urva, Shweta
    Nauck, Michael A.
    Coskun, Tamer
    Cui, Xuewei
    Haupt, Axel
    Benson, Charles
    Loghin, Corina
    DIABETES, 2019, 68
  • [42] The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist
    Urva, S.
    Nauck, M. A.
    Coskun, T.
    Cui, X.
    Haupt, A.
    Benson, C. T.
    Loghin, C.
    DIABETOLOGIA, 2019, 62 : S58 - S58
  • [43] EFFECTS OF TIRZEPATIDE, A NOVEL DUAL GIP AND GLP-1 RECEPTOR AGONIST, ON BIOMARKERS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PROBABLE NASH SUBGROUPS OF PATIENTS WITH TYPE 2 DIABETES (T2D)
    Hartman, Mark
    Loomba, Rohit
    Sanyal, Arun J.
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    HEPATOLOGY, 2019, 70 : 1270A - 1271A
  • [44] Efficacy and safety of once weekly tirzepatide, a dual GIP/GLP-1 receptor agonist versus placebo as monotherapy in people with type 2 diabetes (SURPASS-1)
    Rosenstock, J.
    Wysham, C.
    Frias, J. P.
    Kaneko, S.
    Lee, C. J.
    Lando, L. Fernandez
    Mao, H.
    Cui, X.
    Thieu, V. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 246 - 246
  • [45] IMPACT OF TIRZEPATIDE, A GLP1/GIP RECEPTOR AGONIST, ON THE RELATIVE RISK OF DEVELOPING DIABETIC NEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Ara, Balqees
    Dunlap, Sonya
    Russell, James
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S167 - S167
  • [46] Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
    Pirro, Valentina
    Roth, Kenneth D.
    Lin, Yanzhu
    Willency, Jill A.
    Milligan, Paul L.
    Wilson, Jonathan M.
    Ruotolo, Giacomo
    Haupt, Axel
    Newgard, Christopher B.
    Duffin, Kevin L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02): : 363 - 378
  • [47] Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 382 : 2074
  • [48] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Michael A. Nauck
    David A. D‘Alessio
    Cardiovascular Diabetology, 21
  • [49] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Nauck, Michael A.
    D'Alessio, David A.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [50] Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    Rosenstock, Julio
    Wysham, Carol
    Frias, Juan P.
    Kaneko, Shizuka
    Lee, Clare J.
    Lando, Laura Fernandez
    Mao, Huzhang
    Cui, Xuewei
    Karanikas, Chrisanthi A.
    Thieu, Vivian T.
    LANCET, 2021, 398 (10295): : 143 - 155
12345